Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H12N4O3 |
Molecular Weight | 224.2166 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C2=C(N(CCO)C=N2)C(=O)N(C)C1=O
InChI
InChIKey=NWPRCRWQMGIBOT-UHFFFAOYSA-N
InChI=1S/C9H12N4O3/c1-11-7-6(8(15)12(2)9(11)16)13(3-4-14)5-10-7/h5,14H,3-4H2,1-2H3
Molecular Formula | C9H12N4O3 |
Molecular Weight | 224.2166 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0008081 |
|||
Target ID: CHEMBL226 |
|||
Target ID: CHEMBL2094257 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7325766 |
Primary | ETOFYLLINE Approved Use1. Asthma
2. Chronic obstructive pulmonary disease
3. Chronic bronchitis
4. Emphysema
5. It can be used in premature infants who stop breathing |
||
Primary | ETOFYLLINE Approved Use1. Asthma
2. Chronic obstructive pulmonary disease
3. Chronic bronchitis
4. Emphysema
5. It can be used in premature infants who stop breathing |
|||
Primary | Unknown Approved UseUnknown |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7263108/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
ETOFYLLINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
4.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7263108/ |
200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ETOFYLLINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator​
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
Page: 63.0 |
no | |||
Page: 312.0 |
no | |||
no | ||||
Page: 43.0 |
no | |||
yes [Inhibition 10 uM] | ||||
yes [Inhibition 10 uM] | ||||
Page: 14.0 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 339 | 340 |
no |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 219.0 |
PubMed
Title | Date | PubMed |
---|---|---|
The effects of intravenously administered methylxanthine preparations on the glycoconjugate composition of goblet cells in rabbit tracheal epithelium. | 2002 |
|
Method development for determining the antibacterial linezolid in human serum by micellar electrokinetic capillary chromatography. | 2002 Nov 7 |
|
Investigation of the aqueous dissolution of semicrystalline poly(ethylene oxide) using infrared chemical imaging: the effects of molecular weight and crystallinity. | 2005 Aug |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Simultaneous determination of multi drug components Theophylline, Etofylline, Guaiphenesine and Ambroxol Hydrochloride by validated RP-HPLC method in liquid dosage form. | 2008 Apr |
|
Surface-imprinted nanostructured layer-by-layer film for molecular recognition of theophylline derivatives. | 2008 Oct 21 |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22293828
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:53:20 GMT 2025
by
admin
on
Mon Mar 31 17:53:20 GMT 2025
|
Record UNII |
L164909TBI
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C744
Created by
admin on Mon Mar 31 17:53:20 GMT 2025 , Edited by admin on Mon Mar 31 17:53:20 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1653060
Created by
admin on Mon Mar 31 17:53:20 GMT 2025 , Edited by admin on Mon Mar 31 17:53:20 GMT 2025
|
PRIMARY | |||
|
1892
Created by
admin on Mon Mar 31 17:53:20 GMT 2025 , Edited by admin on Mon Mar 31 17:53:20 GMT 2025
|
PRIMARY | |||
|
m5194
Created by
admin on Mon Mar 31 17:53:20 GMT 2025 , Edited by admin on Mon Mar 31 17:53:20 GMT 2025
|
PRIMARY | Merck Index | ||
|
L164909TBI
Created by
admin on Mon Mar 31 17:53:20 GMT 2025 , Edited by admin on Mon Mar 31 17:53:20 GMT 2025
|
PRIMARY | |||
|
519-37-9
Created by
admin on Mon Mar 31 17:53:20 GMT 2025 , Edited by admin on Mon Mar 31 17:53:20 GMT 2025
|
PRIMARY | |||
|
C008749
Created by
admin on Mon Mar 31 17:53:20 GMT 2025 , Edited by admin on Mon Mar 31 17:53:20 GMT 2025
|
PRIMARY | |||
|
1667
Created by
admin on Mon Mar 31 17:53:20 GMT 2025 , Edited by admin on Mon Mar 31 17:53:20 GMT 2025
|
PRIMARY | |||
|
CHEMBL699
Created by
admin on Mon Mar 31 17:53:20 GMT 2025 , Edited by admin on Mon Mar 31 17:53:20 GMT 2025
|
PRIMARY | |||
|
208-269-8
Created by
admin on Mon Mar 31 17:53:20 GMT 2025 , Edited by admin on Mon Mar 31 17:53:20 GMT 2025
|
PRIMARY | |||
|
SUB07324MIG
Created by
admin on Mon Mar 31 17:53:20 GMT 2025 , Edited by admin on Mon Mar 31 17:53:20 GMT 2025
|
PRIMARY | |||
|
DTXSID5023031
Created by
admin on Mon Mar 31 17:53:20 GMT 2025 , Edited by admin on Mon Mar 31 17:53:20 GMT 2025
|
PRIMARY | |||
|
1107
Created by
admin on Mon Mar 31 17:53:20 GMT 2025 , Edited by admin on Mon Mar 31 17:53:20 GMT 2025
|
PRIMARY | |||
|
100000082085
Created by
admin on Mon Mar 31 17:53:20 GMT 2025 , Edited by admin on Mon Mar 31 17:53:20 GMT 2025
|
PRIMARY | |||
|
113373
Created by
admin on Mon Mar 31 17:53:20 GMT 2025 , Edited by admin on Mon Mar 31 17:53:20 GMT 2025
|
PRIMARY | |||
|
24611
Created by
admin on Mon Mar 31 17:53:20 GMT 2025 , Edited by admin on Mon Mar 31 17:53:20 GMT 2025
|
PRIMARY | RxNorm | ||
|
C80611
Created by
admin on Mon Mar 31 17:53:20 GMT 2025 , Edited by admin on Mon Mar 31 17:53:20 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE | |||
|
PARENT -> METABOLITE ACTIVE |
MINOR
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |